Funder: National Institutes of Health
Due Dates: July 14, 2025 (Earliest submission) | August 13, 2025 (Application) | December 18, 2025 (Application) | August 13, 2026 (Application)
Funding Amounts: Up to $500,000 direct costs/year for UG3 phase (2 years); UH3 phase (up to 3 years) not limited but must reflect project needs.
Summary: Supports phased development and testing of device-based treatments for Substance Use Disorders, advancing toward FDA approval.
Key Information: UG3/UH3 phased award; clear, quantifiable milestones required; clinical trial optional; broad eligibility including foreign organizations.